Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhy combining these two medicines raises real clinical concerns, and what the evidence actually says
You've probably arrived here because you want results faster, here's what's actually happening
It's understandable. You may have read about tirzepatide's trial results, or you're already on semaglutide and wondering whether adding the other medicine could accelerate things. That curiosity is reasonable. The honest answer, though, is that combining Wegovy and Mounjaro isn't a shortcut, it's a compounding of risk without any established clinical rationale.
Tirzepatide (Mounjaro) and semaglutide (Wegovy) both slow gastric emptying and suppress appetite through GLP-1 receptor activity. Tirzepatide also activates GIP receptors, which is what makes it a dual agonist. If you're wondering about whether you can take Mounjaro and Wegovy together, the short answer is no: running both medicines concurrently means two agents are competing for the same receptors simultaneously, and neither the SmPCs nor the clinical trial literature provides any safety or efficacy data for that scenario. What the data does show is that gastrointestinal side effects (nausea, vomiting, diarrhoea) are dose-related and already among the most common reasons people reduce or pause treatment. Stacking the two would almost certainly intensify those effects, and the consequences of severe, persistent vomiting include dehydration and kidney strain. The NHS tirzepatide medicines page and the equivalent semaglutide guidance both flag GI symptoms as the primary side effect profile to monitor.
There is also the question of pancreatitis. The MHRA highlighted acute pancreatitis as an infrequent but serious risk associated with GLP-1 medicines. Combining two agents from this class would compound that risk in ways that have not been studied.
What the trial evidence compares, separately, never together
The most direct head-to-head data comes from SURMOUNT-5, a 72-week open-label trial of 751 adults with obesity and no diabetes, comparing tirzepatide against semaglutide 2.4mg. Tirzepatide produced greater average weight reduction. NICE's appraisal of tirzepatide (TA1026) acknowledged this evidence when recommending Mounjaro for eligible adults.
Semaglutide's own pivotal data, from the STEP 1 trial, showed around 15% average weight reduction over 68 weeks at the 2.4mg maintenance dose, a meaningful result in its own right, confirmed in the STEP 1 paper published in the New England Journal of Medicine. The two medicines have been studied extensively, but always as alternatives to each other. Never in combination.
The table below summarises the key factual differences between the two.
| Feature | Mounjaro (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|
| Mechanism | Dual GIP and GLP-1 receptor agonist | GLP-1 receptor agonist |
| Average weight reduction (pivotal trial) | ~20–21% at 15mg over 72 weeks (SURMOUNT-1) | ~15% at 2.4mg over 68 weeks (STEP 1) |
| UK licence (weight management) | BMI ≥30, or ≥27 with ≥1 weight-related condition | BMI ≥30, or ≥27 with ≥1 weight-related condition |
| Administration | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection |
| Can they be taken together? | No, not licensed, not evidenced, not safe | |
For a fuller side-by-side breakdown of how the two medicines compare on efficacy, cost and eligibility, our Wegovy vs Mounjaro guide covers the evidence in depth.
Switching is different from combining, and it's a clinical decision
What many people asking this question actually mean is: can I move from one medicine to the other? That's a very different situation, and the answer is yes, switching between tirzepatide and semaglutide is something prescribers do in practice, though the timing and approach depend on your individual history. If you're thinking about moving to Mounjaro after Wegovy, or the other direction, those are conversations for a prescriber rather than decisions to make unilaterally.
The question of taking both at the same time is distinct from a switch, and the clinical answer is clear: there is no approved protocol for concurrent use. Similarly, if you're wondering about going from Mounjaro to Wegovy, timing, wash-out and dose context all matter, which is exactly why a prescriber rather than a patient should lead that decision.
At nume, our prescribers review every consultation personally. If you've been on one medicine and want to explore the other, the starting point is a clinical conversation, not a second prescription running alongside the first. For example, if you have already been on tirzepatide and are considering a change, our page on whether you can take Wegovy after taking Mounjaro explains the clinical considerations involved. Which treatment suits your situation is a clinical decision our prescribers make with you.
If you'd like to understand your options, check your eligibility through a free consultation and a named prescriber will review your case the same day.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.